​

Zevra Therapeutics (ZVRA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ZVRA Stock Forecast

Zevra Therapeutics (ZVRA) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $24.67, with a high of $26.00 and a low of $24.00. This represents a 176.26% increase from the last price of $8.93.

- $6 $12 $18 $24 $30 High: $26 Avg: $24.67 Low: $24 Last Closed Price: $8.93

ZVRA Stock Rating

Zevra Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

ZVRA Price Target Upside V Benchmarks

TypeNameUpside
StockZevra Therapeutics176.26%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts136
Avg Price Target$26.00$24.67$22.50
Last Closing Price$8.93$8.93$8.93
Upside/Downside191.15%176.26%151.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2626---8
Dec, 2525---7
Nov, 2535---8
Oct, 2535---8
Sep, 2535---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 30, 2025Brandon FolkesH.C. Wainwright$26.00$8.82194.78%191.15%
Nov 06, 2025Kristen KluskaCantor Fitzgerald$24.00$9.29158.34%168.76%
Nov 06, 2025Canaccord Genuity$24.00$8.95168.16%168.76%
Mar 13, 2025Guggenheim$22.00$7.94177.08%146.36%
Mar 12, 2025JMP Securities$18.00$7.92127.27%101.57%
Feb 04, 2025Zevra Therapeutics to $Guggenheim$21.00$8.13158.30%135.16%
Sep 24, 2024Jonathan AschoffRoth Capital$21.00$7.58177.04%135.16%
Sep 24, 2024Jason McCarthyMaxim Group$25.00$7.58229.82%179.96%
Sep 24, 2024Jason ButlerJMP Securities$17.00$7.58124.27%90.37%
Sep 23, 2024Oren LivnatH.C. Wainwright$20.00$7.92152.53%123.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 30, 2025H.C. WainwrightBuyBuyhold
Nov 06, 2025Cantor FitzgeraldOverweightOverweighthold
Aug 13, 2025CitigroupOutperformOutperformhold
May 14, 2025CitigroupOutperformOutperformhold
Mar 12, 2025CitigroupOutperformOutperformhold
Feb 04, 2025GuggenheimBuyBuyhold
Oct 07, 2024GuggenheimBuyinitialise
Sep 24, 2024Maxim GroupMarket OutperformMarket Outperformhold
Sep 24, 2024Maxim GroupBuyBuyhold
Sep 24, 2024JMP SecuritiesMarket OutperformOutperforminitialise

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.29$-1.20$-1.30$-2.28----
Avg Forecast$-0.86$-1.12$-1.18$-1.89$-0.57$0.78$2.11$3.14
High Forecast$-0.60$-0.77$-1.07$-1.86$2.51$1.42$3.14$4.80
Low Forecast$-1.12$-1.67$-1.35$-1.94$-6.74$0.27$1.44$2.13
Surprise %-66.28%7.14%10.17%20.63%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$28.65M$10.46M$27.46M$23.61M----
Avg Forecast$28.30M$11.24M$25.98M$20.46M$98.27M$174.66M$268.80M$349.60M
High Forecast$34.95M$15.52M$26.25M$20.71M$105.52M$174.66M$377.84M$491.43M
Low Forecast$21.72M$8.56M$25.84M$20.01M$88.12M$174.66M$202.11M$262.87M
Surprise %1.23%-6.96%5.70%15.41%----

Net Income Forecast

$-250M $-160M $-70M $20M $110M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.55M$-41.54M$-46.05M$-105.51M----
Avg Forecast$-30.31M$-39.53M$-46.05M$-67.48M$2.45M$44.53M$81.06M$111.32M
High Forecast$-21.14M$-27.29M$-37.90M$-66.11M$88.93M$50.19M$111.21M$170.03M
Low Forecast$-39.57M$-59.11M$-47.84M$-68.86M$-238.83M$9.67M$50.91M$75.42M
Surprise %-71.78%5.09%-56.35%----

ZVRA Forecast FAQ

Is Zevra Therapeutics stock a buy?

Zevra Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Zevra Therapeutics is a favorable investment for most analysts.

What is Zevra Therapeutics's price target?

Zevra Therapeutics's price target, set by 8 Wall Street analysts, averages $24.67 over the next 12 months. The price target range spans from $24 at the low end to $26 at the high end, suggesting a potential 176.26% change from the previous closing price of $8.93.

How does Zevra Therapeutics stock forecast compare to its benchmarks?

Zevra Therapeutics's stock forecast shows a 176.26% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Zevra Therapeutics over the past three months?

  • January 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Zevra Therapeutics’s EPS forecast?

Zevra Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.57, marking a -75.00% decrease from the reported $-2.28 in 2024. Estimates for the following years are $0.78 in 2026, $2.11 in 2027, and $3.14 in 2028.

What is Zevra Therapeutics’s revenue forecast?

Zevra Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $98.27M, reflecting a 316.17% increase from the reported $23.61M in 2024. The forecast for 2026 is $174.66M, followed by $268.8M for 2027, and $349.6M for 2028.

What is Zevra Therapeutics’s net income forecast?

Zevra Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $2.45M, representing a -102.32% decrease from the reported $-106M in 2024. Projections indicate $44.53M in 2026, $81.06M in 2027, and $111.32M in 2028.